NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Sorafenib for treating advanced hepatocellular carcinoma - NICE TAG TA474

Sorafenib for treating advanced hepatocellular carcinoma - NICE TAG TA474

1.1Sorafenib is recommended as an option for treating advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment, only if the company provides sorafenib within the agreed commercial access arrangement.

1.2This recommendation is not intended to affect treatment with sorafenib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta474

Site by Devopa
© Copyright 2025 NHS. All rights reserved.